Does Medicare Reimbursement Drive Up Drug Launch Prices?

A-Tier
Journal: Review of Economics and Statistics
Year: 2020
Volume: 102
Issue: 5
Pages: 980-993

Authors (2)

David B. Ridley (Duke University) Chung-Ying Lee (not in RePEc)

Score contribution per author:

2.011 = (α=2.01 / 2 authors) × 2.0x A-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

Medicare reimburses health care providers for the drugs they administer. Since 2005, it has reimbursed based on the past price of the drug. Reimbursement on past prices could motivate manufacturers to set higher launch prices because providers become less sensitive to price and because provider reimbursement is higher if past prices were higher. Using data on drug launch prices between 1999 and 2010, we estimate that reimbursement based on past prices caused launch prices to rise dramatically. The evidence is consistent with the 2018 claim from Medicare's administrator that it “creates a perverse incentive for manufacturers to set higher prices.”

Technical Details

RePEc Handle
repec:tpr:restat:v:102:y:2020:i:5:p:980-993
Journal Field
General
Author Count
2
Added to Database
2026-01-29